Nobel Winner Raises $2.1B to Cure Disease with AI

The scientist who won a Nobel Prize for teaching AI to predict protein structures just raised $2.1 billion to turn that breakthrough into actual cures.

Demis Hassabis announced the massive funding round for his company Isomorphic Labs, bringing the dream of AI-designed medicines closer to reality. The British researcher, who calls improving human health "the No. 1 application of AI," plans to push the first AI-created drugs into human clinical trials by late 2026.

The funding came from major investors including Thrive Capital, Alphabet, and the UK Sovereign AI Fund. It marks one of the largest bets yet that artificial intelligence can revolutionize how we discover and develop new treatments.

Hassabis launched Isomorphic Labs in 2021 after his team created AlphaFold, an AI system that predicts how proteins fold and interact inside our bodies. That breakthrough earned him and colleague John Jumper the 2024 Nobel Prize in Chemistry because understanding protein structures is essential to designing effective drugs.

Now the company is using advanced AI to design entirely new drug molecules from scratch. The technology can analyze massive biological datasets far beyond human capability, potentially cutting years off the traditional drug discovery process that typically costs billions and takes over a decade.

Isomorphic has already partnered with pharmaceutical giants Eli Lilly and Novartis to focus on cancer and immune system treatments. The new funding will help scale the AI drug design engine and expand research operations across multiple disease areas.

The Ripple Effect

The investment reflects growing global confidence that AI could fundamentally reshape healthcare. Drug development has remained painfully slow and expensive for decades, with most experimental medicines failing in clinical trials after years of research.

AI offers a different approach by predicting which drug candidates are most likely to work before scientists ever step into a lab. The technology can simulate how millions of potential molecules might interact with disease targets, then help researchers focus only on the most promising options.

Critics rightfully note that AI-designed drugs still need years of rigorous clinical testing and regulatory approval before reaching patients. No shortcut exists for proving a medicine is safe and effective in humans.

But supporters believe we're witnessing the early stages of a medical revolution, where AI helps scientists tackle diseases that have stumped researchers for generations.

The company now has the resources and partnerships to prove whether that vision can become reality for patients waiting for better treatments.